share_log

Short Interest in Innovation Pharmaceuticals Inc. (OTCMKTS:IPIX) Expands By 30.3%

kopsource ·  Apr 19, 2023 16:44

Innovation Pharmaceuticals Inc. (OTCMKTS:IPIX – Get Rating) was the target of a significant increase in short interest in the month of March. As of March 31st, there was short interest totalling 620,700 shares, an increase of 30.3% from the March 15th total of 476,200 shares. Based on an average daily volume of 738,300 shares, the short-interest ratio is presently 0.8 days.

Innovation Pharmaceuticals Stock Down 10.0 %

Shares of OTCMKTS:IPIX traded down $0.00 during midday trading on Wednesday, hitting $0.02. The stock had a trading volume of 203,046 shares, compared to its average volume of 546,743. The stock has a 50 day moving average price of $0.02 and a two-hundred day moving average price of $0.02. Innovation Pharmaceuticals has a 1 year low of $0.01 and a 1 year high of $0.06.

Get Innovation Pharmaceuticals alerts:

About Innovation Pharmaceuticals

(Get Rating)

Innovation Pharmaceuticals, Inc is a clinical stage biotechnology company. It engages in developing therapies with anti-infective, oncology, anti-inflammatory and dermatology applications. The firm's lead cancer compound, Kevetrin, is an anti-cancer drug which has demonstrated the ability in pre-clinical studies to regulate the p53 pathway and attack cancers.

Read More

  • Get a free copy of the StockNews.com research report on Innovation Pharmaceuticals (IPIX)
  • ASML Reports Massive Growth, Management Points To Sluggish 2023
  • Will Analyst Boost Send Lockheed Martin Shares Up, Up and Away?
  • Mullen Automotive: Is The Bloom Off The Rose?
  • Diversified Abbott Laboratories Could Reverse And Move Higher
  • Okta Reversal In Progress While Catalysts Approach

Receive News & Ratings for Innovation Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovation Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment